Electromed, Inc.
AMEX•ELMD
CEO: Mr. James L. Cunniff
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-13
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Contact Information
Market Cap
$193.25M
P/E (TTM)
21.3
3.9
Dividend Yield
--
52W High
$30.73
52W Low
$17.73
52W Range
Rank24Top 10.8%
5.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2026 Data
Revenue
$18.90M+0.00%
4-Quarter Trend
EPS
$0.33+0.00%
4-Quarter Trend
FCF
$3.29M+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Revenue Growth Strong Six months net revenues reached $35.784M, marking a 15.7% increase driven by Homecare segment growth.
Net Income Surges Six months net income totaled $4.897M, reflecting 42.3% growth due to higher revenue and gross profit.
Gross Margin Expansion Gross profit margin improved to 78.3% for six months, up from 78.0% previous period on increased device sales.
New Credit Facility Secured Established $10.0M senior secured revolving credit facility in December 2025; zero principal balance outstanding currently.
Risk Factors
Operating Cash Flow Decline Cash provided by operations fell to $3.195M for six months, down from $5.460M due to working capital changes.
Hospital Sales Volatility Quarterly hospital revenue decreased 9.4% due to lower capital equipment orders impacting short-term sales consistency.
International Revenue Drop Other revenue segment saw sharp quarterly decline of 52.3%, attributed to lower international distributor purchases.
Share Repurchase Spending Financing activities used $3.768M cash, primarily funding $3.766M in common stock repurchase programs during the period.
Outlook
Liquidity Sufficient Forecast Working capital of $36.192M plus available borrowings expected to meet liquidity needs for next twelve months.
R&D Tax Acceleration Company plans to accelerate remaining R&D deductions over one year, estimating $428,000 cash tax reduction in 2026.
Capital Expenditure Funding Planned equipment purchases expected to be financed via operating cash flows or borrowings under new credit facility.
Accounting Standard Evaluation Evaluating impact of recently issued accounting standards ASU 2023-09 and ASU 2024-03 for future adoption periods.
Peer Comparison
Revenue (TTM)
$436.97M
$348.67M
$311.14M
Gross Margin (Latest Quarter)
92.4%
87.3%
86.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VMD | $359.78M | 23.7 | 10.9% | 7.4% |
| CATX | $358.02M | -3.5 | -41.3% | 0.6% |
| CVRX | $223.65M | -4.2 | -99.3% | 48.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.4%
Steady Growth
4Q Net Income CAGR
13.4%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 11, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data